Biotech Values

[ghmm]

I don't think one makes a (reasonable) bet on a Phase 1 program getting partnered moving the stock. Plus, they are going to do MAD study too that likely won't have results till early next year.

The burn may not be quite so bad but I agree on a raise (I think in the ~6 - 12 month range). The Breast cancer trial likely won't really start till '12. They'll probably go through some burn getting sites set up and the like but I don't think they get any significant enrollment started this year. The ovarian I had suspected they wouldn't start the (phase 3) trial till they had the extension data. Then I got my hopes they would start it before now I am back to it doesn't start till they review data and with FDA (pre Phase 3) so I don't see much spend on that even in '12.

I think the ovarian extension (first 60) enrolled pretty quick and think the 50 additional were progressing well (according to calls). I haven't made a timeline chart so can't say when things fall into play but am fairly certain the options are related to Ovarian results.